135065-64-4

Basic information

• Product Name: 4-Morpholinecarboxylic acid, 2-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-, 1,1-dimethylethyl ester, (R)-
• CAS NO: 135065-64-4
• Molecular Formula: C17H25NO6S
• Molecular Weight: 371.455
• Mol File: 135065-64-4.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: 4-Morpholinecarboxylic acid, 2-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-, 1,1-dimethylethyl ester, (R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Morpholinecarboxylic acid, 2-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-, 1,1-dimethylethyl ester, (R)-(135065-64-4)
• EPA Substance Registry System: 4-Morpholinecarboxylic acid, 2-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-, 1,1-dimethylethyl ester, (R)-(135065-64-4)

Safety Data

• Hazardous Substances Data: 135065-64-4(Hazardous Substances Data)

Upstream product

• 135065-71-3 (R)-2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 156925-22-3 (2R)-2-hydroxymethylmorpholine 
• 919286-64-9 (R)-2-chloro-N-(2,3-dihydroxypropyl)acetamide 
• 919286-65-0 (R)-6-(hydroxymethyl)morpholin-3-one 
• 98-59-9 p-toluenesulfonyl chloride 
• 135097-68-6 tert-butyl (2R)-2-[(benzyloxy)methyl]morpholine-4-carboxylate 
• 135065-70-2 (2R)-2-[(benzyloxy)methyl]morpholine 
• 929278-92-2 {(2R)-4-[(4-methylphenyl)sulfonyl]-2-morpholinyl}methanol 
• 929278-90-0 (2R)-4-[(4-methylphenyl)sulfonyl]-2-{[(phenylmethyl)oxy]methyl}-morpholine 
• 929278-88-6 N-(2-hydroxyethyl)-N-{(2R)-2-hydroxy-3-[(phenylmethyl)oxy]propyl}-4-methylbenzenesulfonamide 
• 929278-86-4 (2R)-1-[(2-hydroxyethyl)amino]-3-[(phenylmethyl)oxy]-2-propanol 

Downstream Products

• 135065-71-3 (R)-2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester 
• 879403-42-6 tert-butyl (2S)-2-(aminomethyl)morpholine-4-carboxylate 

Relevant articles and documents

NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS

The present invention covers substituted Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.

1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES

The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

SERINE/THREONINE KINASE INHIBITORS

Compounds having the formula I, or a pharmaceutically acceptable salt thereof, wherein R1, R2, X1, X2, and Ar are as defined herein, are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders using such compounds.